ABIVAX Société Anonyme (AAVXF)
| Previous close | 32.00 |
| Open | 32.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 32.00 - 32.00 |
| 52-week range | 21.14 - 43.97 |
| Volume | 38 |
| Avg. volume | 31 |
| Market cap | 466.96M |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.13 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis
DGAP-News: ABIVAX / Key word(s): Study results18.10.2021 / 18:00 The issuer is solely responsible for the content of this announcement.ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained as well as further improved efficacy Favorable safety and tolerability profile continues to support ABX464 chronic use potent
- EQS Group
Abivax announces the release of its 2021 half-year financial report
DGAP-News: ABIVAX / Key word(s): Half Year Report30.09.2021 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax announces the release of its 2021 half-year financial report PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publ
- EQS Group
Abivax late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021
DGAP-News: ABIVAX / Key word(s): Conference28.09.2021 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021Principal investigator Prof. Séverine Vermeire, M.D., Ph.D, to present Abivax's late-breaking abstract on ABX464 phase 2b study results in ulcerative colitis (UC)October 4, 2021, at 10:42-10:54 am CESTAbivax will also be hosting a Live Industry Symposium on ABX464's po
